Jasper Enterprise Value Over E B I T D A from 2010 to 2024

JSPRW Stock  USD 0.20  0.02  9.09%   
Jasper Therapeutics Enterprise Value Over EBITDA yearly trend continues to be fairly stable with very little volatility. Enterprise Value Over EBITDA will likely drop to 0.03 in 2024. During the period from 2010 to 2024, Jasper Therapeutics Enterprise Value Over EBITDA regression line of quarterly data had mean square error of  815.96 and geometric mean of  10.40. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
0.02673371
Current Value
0.0254
Quarterly Volatility
47.85381934
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 11.2 M or Other Operating Expenses of 40 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.1. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Jasper Therapeutics Correlation against competitors.
For more information on how to buy Jasper Stock please use our How to Invest in Jasper Therapeutics guide.

Latest Jasper Therapeutics' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Jasper Therapeutics over the last few years. It is Jasper Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jasper Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Jasper Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean65.37
Geometric Mean10.40
Coefficient Of Variation73.20
Mean Deviation43.59
Median98.06
Standard Deviation47.85
Sample Variance2,290
Range98.3594
R-Value(0.82)
Mean Square Error815.96
R-Squared0.67
Significance0.0002
Slope(8.75)
Total Sum of Squares32,060

Jasper Enterprise Value Over E B I T D A History

2024 0.0254
2023 0.0267
2022 0.44
2021 -0.24
2020 -0.3

About Jasper Therapeutics Financial Statements

Jasper Therapeutics investors use historical fundamental indicators, such as Jasper Therapeutics' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jasper Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 0.03  0.03 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.